Khiron updates fully operational Colombian Lab Facilities (TSXV: KHRN)

Subsequent to my interview with Chris Naprawa, President of Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF), the company issued an update of operations. The highlights are:

• State-of-the-art, 14,000 square foot GMP compliant cannabis extraction lab and ISO 17025 compliant cannabis testing lab includes full capabilities in Ultra high and High performance liquid chromatography ("UHPLC" & "HPLC") technology, gas chromatography, stability testing, microbiology and heavy metals testing.

• Physical chemical cannabis testing lab has a capacity of up to 70 daily UHPLC & HPLC cannabinoid samples, 15 daily gas chromatography samples, and 2,000 monthly heavy metals samples. Microbiological testing lab has a capacity of up to 20 daily samples.

• State-of-the-art testing lab allows the Company to fully test every aspect of its vertical integration from soil and water to flower to extract, ensuring a high-quality product that will be delivered to patients across Latin America.

• Company reaffirms full grow site commercialization, starting with already approved CBD strains, anticipated in Q3 2019.

• Cultivation capabilities operate within the most up-to-date country THC quotas assigned by the International Narcotics Control Board (INCB) to meet domestic demand, including to serve more than 119,000 patients at the Company's ILANS clinics.

• Significant investment in cultivation and production facilities ensures capacity and infrastructure to meet the most stringent local testing requirements to sell in the Colombian market.

• (read full press release here)